The State Trading Organization (STO), in collaboration with AstraZeneca, has introduced two groundbreaking respiratory healthcare products in the Maldives — Symbicort Turbuhaler and Pulmicort Respules. These innovations are set to transform the management of asthma and chronic obstructive pulmonary disease (COPD) in the country.
The official launch took place on Sunday at Dharumavantha Hospital, bringing together nearly 60 physicians. The event included in-depth discussions on evidence-based treatments aimed at improving patient care and outcomes.
Renowned Indian pulmonologist Dr. Rennis Davis delivered the keynote address, focusing on the importance of adhering to Global Initiative for Asthma (GINA) guidelines. He highlighted the shift in asthma and COPD treatment strategies, emphasizing the reduced reliance on short-acting beta-agonists (SABA) and the importance of maintenance and reliever management.
Revolutionary Treatment Options
Symbicort Turbuhaler, a dry powder inhaler, is designed for ease of use, offering faster and more effective relief compared to traditional SABA relievers. It combines convenience with superior symptom control, making it a vital tool for patients.
Pulmicort Respules, another innovative product, rapidly penetrates the airway mucus layer within six minutes, delivering significant pulmonary effects in just 30 minutes. This targeted approach minimizes asthma symptoms and reduces exacerbation risks, providing a safer and more efficient alternative to systemic steroids.
Commitment to Community Healthcare
STO emphasized its dedication to addressing critical medical needs in the Maldives through the introduction of advanced healthcare solutions. By partnering with leading global healthcare companies, the organization aims to improve the quality of care and enhance the well-being of the Maldivian population.
The launch of these products signifies a step forward in respiratory care, offering hope and better health outcomes for individuals suffering from asthma and COPD in the Maldives.
